Literature DB >> 2142402

Dexamethasone-induced plasminogen activator inhibitor: characterization, purification, and preparation of monoclonal antibodies.

A Oikarinen1, M Höyhtyä, M Järvinen.   

Abstract

The effects of dexamethasone on protein synthesis were studied in human fibrosarcoma (HT-1080) cells. Dexamethasone induced a new protein of 46 kD which was rapidly secreted into the medium, while neither progesterone nor estradiol would induce the synthesis of this protein and only a small increase in its amount could be seen in the presence of testosterone. The 46 kD protein was partially purified by ammonium sulfate precipitation and gel filtration and mouse monoclonal antibodies to it were produced in mouse hybrid cells. Altogether 13 positive clones were found, of which six reacted only with native and seven reacted with the unreduced 46 kD protein in Western blotting. It was possible by using polyclonal antibodies to plasminogen activator inhibitor type I (PAI-1) and purified plasminogen activator inhibitor type I to confirm that the 46 kD protein purified and characterized here was PAI-1. In addition, the 46 kD protein clearly inhibited plasminogen activation, thus further confirming that protein isolated was an inhibitor of plasminogen activator. Since the induction of PAI-1 by dexamethasone was very extensive, it is possible that glucocorticoids regulate proteolysis and fibrinolysis in vivo by increasing the amount of the inhibitor of plasminogen activator and thus preventing the activation of plasminogen to plasmin. The reduction of activation of plasminogen to plasmin by glucocorticoid-induced inhibitor could be of great importance, e.g., in various blistering diseases, in metastases from malignant cells, and in the migration of inflammatory cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2142402     DOI: 10.1007/bf00372614

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  23 in total

Review 1.  The role of proteases in the pathogenesis of bullous dermatoses.

Authors:  K Takamori; T Yoshiike; S Morioka; H Ogawa
Journal:  Int J Dermatol       Date:  1988-10       Impact factor: 2.736

Review 2.  Mechanism of action of glucocorticoids.

Authors:  E B Thompson; M E Lippman
Journal:  Metabolism       Date:  1974-02       Impact factor: 8.694

3.  Characterization of a newly derived human sarcoma cell line (HT-1080).

Authors:  S Rasheed; W A Nelson-Rees; E M Toth; P Arnstein; M B Gardner
Journal:  Cancer       Date:  1974-04       Impact factor: 6.860

4.  A film detection method for tritium-labelled proteins and nucleic acids in polyacrylamide gels.

Authors:  W M Bonner; R A Laskey
Journal:  Eur J Biochem       Date:  1974-07-01

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 6.  Control of gene expression by glucocorticoid hormones.

Authors:  G G Rousseau
Journal:  Biochem J       Date:  1984-11-15       Impact factor: 3.857

7.  Plasminogen activator inhibitor type 1 biosynthesis and mRNA level are increased by dexamethasone in human fibrosarcoma cells.

Authors:  P A Andreasen; C Pyke; A Riccio; P Kristensen; L S Nielsen; L R Lund; F Blasi; K Danø
Journal:  Mol Cell Biol       Date:  1987-08       Impact factor: 4.272

8.  Hormonal regulation of extracellular plasminogen activators and Mr approximately 54,000 plasminogen activator inhibitor in human neoplastic cell lines, studied with monoclonal antibodies.

Authors:  P A Andreasen; T H Christensen; J Y Huang; L S Nielsen; E L Wilson; K Danø
Journal:  Mol Cell Endocrinol       Date:  1986-05       Impact factor: 4.102

9.  Urokinase- and tissue-type plasminogen activators in keratinocytes during wound reepithelialization in vivo.

Authors:  J Grøndahl-Hansen; L R Lund; E Ralfkiaer; V Ottevanger; K Danø
Journal:  J Invest Dermatol       Date:  1988-06       Impact factor: 8.551

10.  Dexamethasone modulates the metabolism of type IV collagen and fibronectin in human basement-membrane-forming fibrosarcoma (HT-1080) cells.

Authors:  A Oikarinen; T Salo; L Ala-Kokko; K Tryggvason
Journal:  Biochem J       Date:  1987-07-01       Impact factor: 3.857

View more
  4 in total

1.  Inhibition of sulfur mustard-increased protease activity by niacinamide, N-acetyl-L-cysteine or dexamethasone.

Authors:  F M Cowan; C A Broomfield; W J Smith
Journal:  Cell Biol Toxicol       Date:  1992 Apr-Jun       Impact factor: 6.691

2.  Hypercoagulability in Cushing's syndrome: the role of specific haemostatic and fibrinolytic markers.

Authors:  Darko Kastelan; Tina Dusek; Ivana Kraljevic; Ozren Polasek; Zlatko Giljevic; Mirsala Solak; Silva Zupancic Salek; Jozo Jelcic; Izet Aganovic; Mirko Korsic
Journal:  Endocrine       Date:  2009-04-21       Impact factor: 3.633

3.  Markers of activation of coagulation and fibrinolysis in patients with Cushing's syndrome.

Authors:  L M Fatti; B Bottasso; C Invitti; R Coppola; F Cavagnini; P M Mannucci
Journal:  J Endocrinol Invest       Date:  2000-03       Impact factor: 5.467

4.  Hypertension and other morbidities with Cushing's syndrome associated with corticosteroids: a review.

Authors:  Melpomeni Peppa; Maria Krania; Sotirios A Raptis
Journal:  Integr Blood Press Control       Date:  2011-03-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.